PPD, Inc. has established four practice areas through PPD Consulting: biosimilars, adaptive trial design, China regulatory strategy and cardiovascular outcomes studies. These services were established to help clients meet unique product development challenges.
PPD Consulting offers clinical, regulatory and commercial program strategies to a range of development programs for small molecules, vaccines, biologics, biosimilars, diagnostics and devices. The team also works with biopharma and medical device companies to help address gaps in strategic resourcing and to gain strategic insight for long-term development and planning activities. PPD’s consulting services with biosimilar development aims to help clients to select appropriate endpoints, design more efficient clinical trials and develop effective regulatory strategies.
“PPD has a strong team of physicians, regulatory experts, scientists and biostatisticians with extensive experience in creating and implementing product development plans from preclinical through post-approval on global and local levels,” said Christine Dingivan, M.D., chief medical officer of PPD. “We have aligned our consulting practice to the areas where we continue to see a strong need for our services to help our clients address significant regulatory and market challenges.”